Introduction Nearly 60% of patients with non-small cell lung cancer (NSCLC) present with
metastatic disease, and approximately 20% have brain metastases (BrMs) at diagnosis …

Purpose: We report the final analysis of JVDL (NCT02789345), which examined the
combination of the EGFR tyrosine kinase inhibitor (TKI) osimertinib plus the VEGFR2 …

Patients with advanced non-small cell lung cancer (NSCLC) are prone to brain metastases
(BM), which essentially include brain parenchymal metastases (PM) and leptomeningeal …

Objective To clarify the distribution of lorlatinib in the brain and elucidate the molecular
mechanisms of lorlatinib penetration across the blood‐brain barrier (BBB). Methods …

The effects of smoking on survival in BM patients have yet to be reviewed and meta-
analysed. However, previous studies have shown that smokers had a greater risk of dying …

Background Anlotinib is a multi-target tyrosine kinase inhibitor (TKI) independently
developed by China, which can inhibit tumor angiogenesis and tumor cell proliferation. The …

Background Brain metastasis (BM) causes high morbidity and mortality rates in lung cancer
(LC) patients. The present study aims to develop models for predicting the development and …

Objective: To investigate the risk factors of brain metastases and its influence on the
prognosis of patients with complete resected non-small cell lung cancer (NSCLC). Methods …

背景EGFR 基因突变阳性肺腺癌脑转移患者的治疗仍是目前的研究热点和有争议的问题,
没有标准的治疗模式. 目的探讨EGFR 基因突变阳性肺腺癌脑转移患者经脑转移治疗后发生颅内 …

Background The occurrence of cardiovascular events is a major cause of death in patients
with cancer. Small studies have documented a connection between specific brain alterations …